Journal of Dali University ›› 2019, Vol. 4 ›› Issue (2): 59-.

Previous Articles     Next Articles

Clinical Application of Conbercept for Treatment of Diabetic Retinopathy and Macular Edema

Cheng Fei, Jia Yunqin, Han Peiyan, Chen Yinchao, Zhou Xia, Duan Zhiguang   

  1. （1. Clinical College, Dali University, Dali, Yunnan 671000, China; 2. Ophthalmology Department, The Third Affiliated Hospital of Dali
    University, Dali, Yunnan 671000, China）
  • Received:2018-09-21 Revised:2018-12-07 Online:2019-02-15 Published:2019-02-15

PDF (PC)

86

Abstract: 〔Abstract〕Objective: To evaluate the efficacy and safety of Conbercept intravitreal injections in treatment of diabetic retinopathy,
and its effects on vitrectomy for proliferative diabetic retinopathy（PDR）. Methods: We retrospectively analyzed 56 patients（80 eyes）
with DR who received Conbercept intravitreal injection in our hospital. 30 patients（62 eyes）had NPDR, and 26（28 eyes）with severe
PDR underwent vitreous resection（PPV）. The latter was randomly divided into the IVC&PPV group in which 15 patients（16 eyes）
were treated with conbercept intravitreal injection in combination with vitrectomy and the PPV group in which 11patients（12 eyes）
underwent vitrectomy. Results: Among patients with NPDR, their diabetic retinopathy was improved in varying degrees,
neovascularization was significantly inhibited, macular edema was improved and absorbed, and visual acuity was corrected in different
degrees. IVC/PPV was significantly favorable for surgical operations. Conclusion: Intravitreal injection of Conbercept is an effective
treatment for NPDR. For severe PDR patients who are undergoing vitrectomy, it can effectively reduce the difficulty of surgery and
reduce the occurrence of surgical complications, so it is the mainstream choice for the treatment of diabetic retinopathy.

Key words: 〔Key words〕Conbercept, diabetic retinopathy, applied research